The new missense G376V-TDP-43 variant induces late-onset distal myopathy but not amyotrophic lateral sclerosis.

TARDBP ALS TDP-43 cryptic exons distal myopathy protein aggregation skeletal muscle

Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
11 Dec 2023
Historique:
received: 06 07 2023
revised: 20 11 2023
accepted: 08 12 2023
medline: 11 12 2023
pubmed: 11 12 2023
entrez: 11 12 2023
Statut: aheadofprint

Résumé

TDP-43-positive inclusions in neurons are a hallmark of several neurodegenerative diseases including familial amyotrophic lateral sclerosis (fALS) caused by pathogenic TARDBP variants as well as more common non-Mendelian sporadic ALS (sALS). Here we report a G376V-TDP-43 missense variant in the C-terminal prion-like domain of the protein in two French families affected by an autosomal dominant myopathy but not fulfilling diagnostic criteria for ALS. Patients from both families presented with progressive weakness and atrophy of distal muscles, starting in their 5th-7th decade. Muscle biopsies revealed a degenerative myopathy characterized by accumulation of rimmed (autophagic) vacuoles, disruption of sarcomere integrity and severe myofibrillar disorganization. The G376 V variant altered a highly conserved amino acid residue and was absent in databases on human genome variation. Variant pathogenicity was supported by in silico analyses and functional studies. The G376 V mutant increased the formation of cytoplasmic TDP-43 condensates in cell culture models, promoted assembly into high molecular weight oligomers and aggregates in vitro, and altered morphology of TDP-43 condensates arising from phase separation. Moreover, the variant led to the formation of cytoplasmic TDP-43 condensates in patient-derived myoblasts and induced abnormal mRNA splicing in patient muscle tissue. The identification of individuals with TDP-43-related myopathy but not ALS implies that TARDBP missense variants may have more pleiotropic effects than previously anticipated and support a primary role for TDP-43 in skeletal muscle pathophysiology. We propose to include TARDBP screening in the genetic work-up of patients with late-onset distal myopathy. Further research is warranted to examine the precise pathogenic mechanisms of TARDBP variants causing either a neurodegenerative or myopathic phenotype.

Identifiants

pubmed: 38079474
pii: 7469293
doi: 10.1093/brain/awad410
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.

Auteurs

Julia Zibold (J)

Friedrich-Baur Institute at the Department of Neurology, University Hospital, LMU Munich, 80336 Munich, Germany.

Lola E R Lessard (LER)

Institut NeuroMyoGène-PGNM, Faculté de Médecine Rockefeller, Université Claude Bernard Lyon, 69008 Lyon, France.
Service d'Electroneuromyographie et de pathologies neuromusculaires, 69677 Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France.

Flavien Picard (F)

Institut NeuroMyoGène-PGNM, Faculté de Médecine Rockefeller, Université Claude Bernard Lyon, 69008 Lyon, France.

Lara Gruijs da Silva (LG)

Johannes Gutenberg University (JGU), Biocenter, Institute of Molecular Physiology, 55128 Mainz, Germany.
Graduate School of Systemic Neurosciences (GSN), 82152 Planegg-Martinsried, Germany.
Center for Anatomy, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany.

Yelyzaveta Zadorozhna (Y)

Johannes Gutenberg University (JGU), Biocenter, Institute of Molecular Physiology, 55128 Mainz, Germany.
International PhD Programme (IPP) of the Institute of Molecular Biology (IMB), 55128 Mainz, Germany.

Nathalie Streichenberger (N)

Institut NeuroMyoGène-PGNM, Faculté de Médecine Rockefeller, Université Claude Bernard Lyon, 69008 Lyon, France.
Département d'Anatomo-Pathologie, Groupement Hospitalier Est, Hospices Civils de Lyon, 69677 Lyon, France.

Edwige Belotti (E)

Institut NeuroMyoGène-PGNM, Faculté de Médecine Rockefeller, Université Claude Bernard Lyon, 69008 Lyon, France.

Alexis Osseni (A)

Institut NeuroMyoGène-PGNM, Faculté de Médecine Rockefeller, Université Claude Bernard Lyon, 69008 Lyon, France.

Andréa Emerit (A)

Institut NeuroMyoGène-PGNM, Faculté de Médecine Rockefeller, Université Claude Bernard Lyon, 69008 Lyon, France.

Elisabeth Errazuriz-Cerda (E)

Plateforme d'imagerie CIQLE, 69008 Lyon, France.

Laurence Michel-Calemard (L)

Institut NeuroMyoGène-PGNM, Faculté de Médecine Rockefeller, Université Claude Bernard Lyon, 69008 Lyon, France.
Service Biochimie et Biologie Moléculaire, Centre de biologie et pathologie Est, Hospices civils de Lyon, 69677 Lyon, France.

Rita Menassa (R)

Institut NeuroMyoGène-PGNM, Faculté de Médecine Rockefeller, Université Claude Bernard Lyon, 69008 Lyon, France.
Service Biochimie et Biologie Moléculaire, Centre de biologie et pathologie Est, Hospices civils de Lyon, 69677 Lyon, France.

Laurent Coudert (L)

Institut NeuroMyoGène-PGNM, Faculté de Médecine Rockefeller, Université Claude Bernard Lyon, 69008 Lyon, France.

Manuela Wiessner (M)

Friedrich-Baur Institute at the Department of Neurology, University Hospital, LMU Munich, 80336 Munich, Germany.

Rolf Stucka (R)

Friedrich-Baur Institute at the Department of Neurology, University Hospital, LMU Munich, 80336 Munich, Germany.

Thomas Klopstock (T)

Friedrich-Baur Institute at the Department of Neurology, University Hospital, LMU Munich, 80336 Munich, Germany.
German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.

Francesca Simonetti (F)

Johannes Gutenberg University (JGU), Biocenter, Institute of Molecular Physiology, 55128 Mainz, Germany.
Graduate School of Systemic Neurosciences (GSN), 82152 Planegg-Martinsried, Germany.
German Center for Neurodegenerative Diseases (DZNE), 81377 Munich, Germany.

Saskia Hutten (S)

Johannes Gutenberg University (JGU), Biocenter, Institute of Molecular Physiology, 55128 Mainz, Germany.

Takashi Nonaka (T)

Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan.

Masato Hasegawa (M)

Dementia Research Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan.

Tim M Strom (TM)

Institute of Human Genetics, Klinikum rechts der Isar, Technical University Munich, 81675 Munich, Germany.

Emilien Bernard (E)

Institut NeuroMyoGène-PGNM, Faculté de Médecine Rockefeller, Université Claude Bernard Lyon, 69008 Lyon, France.
Service d'Electroneuromyographie et de pathologies neuromusculaires, 69677 Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France.

Elisabeth Ollagnon (E)

Service de Génétique, Neurogénétique et Médecine Prédictive, 69004 Hôpital de la Croix-Rousse, Hospices Civils de Lyon, France.

Andoni Urtizberea (A)

Centre de Référence Neuromusculaire, Hôpital Marin - APHP, 64701 Hendaye, France.

Dorothee Dormann (D)

Johannes Gutenberg University (JGU), Biocenter, Institute of Molecular Physiology, 55128 Mainz, Germany.
Munich Cluster for Systems Neurology (SyNergy), 81377 Munich, Germany.
Institute of Molecular Biology (IMB), 55128 Mainz, Germany.

Philippe Petiot (P)

Centre de santé Medicina Rockefeller, 69008 Lyon, France.

Laurent Schaeffer (L)

Institut NeuroMyoGène-PGNM, Faculté de Médecine Rockefeller, Université Claude Bernard Lyon, 69008 Lyon, France.

Jan Senderek (J)

Friedrich-Baur Institute at the Department of Neurology, University Hospital, LMU Munich, 80336 Munich, Germany.

Pascal Leblanc (P)

Institut NeuroMyoGène-PGNM, Faculté de Médecine Rockefeller, Université Claude Bernard Lyon, 69008 Lyon, France.

Classifications MeSH